- Home
- STRO vs DSM Comparison
STRO vs DSM Comparison
Compare STRO & DSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- DSM
- Stock Information
- Founded
- STRO 2003
- DSM 1989
- Country
- STRO United States
- DSM United States
- Employees
- STRO N/A
- DSM N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- DSM Investment Managers
- Sector
- STRO Health Care
- DSM Finance
- Exchange
- STRO Nasdaq
- DSM Nasdaq
- Market Cap
- STRO 292.6M
- DSM 303.5M
- IPO Year
- STRO 2018
- DSM N/A
- Fundamental
- Price
- STRO $2.84
- DSM $6.12
- Analyst Decision
- STRO Strong Buy
- DSM
- Analyst Count
- STRO 7
- DSM 0
- Target Price
- STRO $12.14
- DSM N/A
- AVG Volume (30 Days)
- STRO 1.0M
- DSM 161.7K
- Earning Date
- STRO 11-13-2024
- DSM 01-01-0001
- Dividend Yield
- STRO N/A
- DSM 3.97%
- EPS Growth
- STRO N/A
- DSM N/A
- EPS
- STRO N/A
- DSM N/A
- Revenue
- STRO $160,955,000.00
- DSM N/A
- Revenue This Year
- STRO N/A
- DSM N/A
- Revenue Next Year
- STRO N/A
- DSM N/A
- P/E Ratio
- STRO N/A
- DSM N/A
- Revenue Growth
- STRO 230.90
- DSM N/A
- 52 Week Low
- STRO $2.45
- DSM $4.69
- 52 Week High
- STRO $6.13
- DSM $6.05
- Technical
- Relative Strength Index (RSI)
- STRO 41.69
- DSM 55.38
- Support Level
- STRO $2.66
- DSM $6.09
- Resistance Level
- STRO $2.86
- DSM $6.18
- Average True Range (ATR)
- STRO 0.19
- DSM 0.05
- MACD
- STRO 0.02
- DSM 0.02
- Stochastic Oscillator
- STRO 78.00
- DSM 73.91
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.